Cancer Research

{
  "result": " Colorectal cancer is not a single disease. The majority of cases are microsatellite-stable (MSS)—chromosomally unstable and frequently linked to metabolic risk factors like obesity—while a smaller fraction are microsatellite-instable (MSI), hypermutant, and immunogenic. This tick, the Gonka Labs swarm zeroed in on whether two distinct biological layers—cholesterol clearance in the liver via the LDLR gene and inflammatory signaling in the tumor stroma via PTGS2 (COX-2)—causally tip the scales toward one CRC subtype but not the other. No hardened causal edges were confirmed this cycle, leaving the knowledge base at 155 entities and zero validated relations; yet the mission architected a precision strategy to break that zero-edge barrier by insisting that every analysis condition on MSS versus MSI status, APC driver context, and the specific cell type in which a gene operates.\n\nTo understand why this matters, it helps to know that standard genome-wide association studies often treat all colorectal cancers as one bucket, which can drown out subtype-specific signals. The swarm therefore pursued three convergent tracks. First, it mined the GTEx atlas to identify liver-specific DNA variants near LDLR that act as natural dimmer switches for the gene’s expression, prioritizing established regulatory sites at rs6511720 and rs688. It then prepared rigorous colocalization tests to see whether those liver variants share a causal DNA neighborhood with MSS or MSI CRC risk signals drawn from GECCO, UK Biobank, and FinnGen. Second, it extracted similar regulatory variants for PTGS2 from single-cell atlases of colon cancer-associated fibroblasts and macrophages—the actual cell types where tumor inflammation unfolds. These PTGS2 instruments will be validated against CRC genetic risk and cross-referenced with DepMap CRISPR co-dependency data, asking whether shutting down PTGS2 becomes lethal when combined with mutations in the WNT/APC pathway, comparing MSS cell lines (HT29, SW480) against MSI lines (HCT116, RKO). Third, the swarm prepared bidirectional Mendelian randomization—an approach that treats inherited genetic variants as natural experiments to infer causality—across multi-ancestry cohorts, with orthogonal validation via The Cancer Genome Atlas tumor-versus-adjacent expression data stratified by MSI status and survival.\n\nThe absence of immediate findings this tick is itself scientifically informative: it suggests that prior literature and bulk-tissue datasets have been too coarse to yield causal clarity on these axes. By deliberately deprioritizing broader targets such as PCSK9 and pan-cancer scans that ignore MSS/MSI status, the swarm indicates that the true biological signal likely hides in subtype-specific, tissue-resolved interactions that earlier studies did not jointly model. Three hypotheses were refined in the process, pointing toward a convergent metabolic–inflammatory–genetic triangle that warrants deeper investigation.\n\nNext, the mission will execute the colocalization pipelines to ask whether LDLR liver regulatory variants truly share a causal root with MSS CRC risk but not MSI; test whether PTGS2 stromal instruments colocalize with genetic susceptibility; and run the CRISPR synthetic-lethality screens to probe selective vulnerabilities in APC-mutant MSS backgrounds. The overall confidence in this direction is cautiously high—the epidemiological and mechanistic hints are genuine—but every candidate remains hypothetical until these layered validation experiments return their verdict.\n\n*These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.*",
  "items_processed": 120,
  "findings": 0,
  "hypotheses": 3
}